To identify drugs granted FDA pediatric exclusivity in 2023, one must consult official FDA reports or databases. Pediatric exclusivity is an extension of market exclusivity granted to a drug manufacturer who conducts clinical trials in pediatric populations as requested by the FDA. This extension typically adds six months to the existing patent and exclusivity periods.
What triggers FDA pediatric exclusivity?
Pediatric exclusivity is granted when a drug sponsor, at the request of the FDA, conducts studies in children. These studies aim to determine the drug's safety and effectiveness in this age group, and whether the labeling needs to be amended to reflect pediatric use. If the studies are completed and submitted to the FDA before the patent or existing exclusivity expires, the manufacturer earns an additional six months of exclusivity [1]. This incentivizes research into pediatric drug development, an area historically underserved [2].
How does pediatric exclusivity affect drug patents?
Pediatric exclusivity is distinct from patent protection but can extend the period during which a drug is protected from generic competition. When granted, it tacks on six months to the end of the drug's existing market exclusivity, whether that exclusivity stems from a patent or a regulatory exclusivity period. This means generic manufacturers cannot market their versions of the drug until this extended period expires [1].
Where can I find a list of drugs with 2023 pediatric exclusivity?
A definitive, publicly available list specifically detailing all drugs granted FDA pediatric exclusivity in 2023 is not aggregated into a single, easily accessible report by the FDA. However, information can be found by reviewing FDA communications, such as Federal Register notices, and by tracking drug approvals and patent data. Websites like DrugPatentWatch.com often monitor and compile this type of information, providing insights into patent cliffs and exclusivity expirations, which would include extensions due to pediatric studies [3]. Researchers and industry professionals typically rely on specialized databases and subscription services for comprehensive tracking.
When does pediatric exclusivity typically expire?
The expiration of pediatric exclusivity is tied to the original patent or exclusivity expiration date plus the six-month extension. For example, if a drug's patent was set to expire on December 31, 2023, and it received pediatric exclusivity, the effective exclusivity would then extend to June 30, 2024 [1]. The exact expiration date depends on when the original exclusivity was scheduled to end.
What are the benefits of pediatric exclusivity for drug developers?
The primary benefit for drug developers is the extended period of market exclusivity, which can translate to significant revenue generation for an additional six months. This provides a financial incentive to undertake the costly and complex process of pediatric clinical trials. Furthermore, it allows for the development of crucial safety and efficacy data for children, potentially leading to improved treatment protocols for pediatric patients [2].
How does pediatric exclusivity differ from other forms of market protection?
Pediatric exclusivity is a regulatory incentive that extends existing market protection by six months upon successful completion of pediatric studies. It is different from patent protection, which is a form of intellectual property granted by the patent office for a novel invention, typically lasting 20 years from the filing date. It also differs from other regulatory exclusivities, such as New Chemical Entity (NCE) exclusivity, which lasts for five years, or Orphan Drug exclusivity, which provides seven years of market protection for drugs treating rare diseases [1].
What is the impact of pediatric exclusivity on generic drug availability?
Pediatric exclusivity delays the market entry of generic competitors. Generic manufacturers are prohibited from launching their products during the extended exclusivity period. This delay can mean that patients and healthcare systems continue to pay higher brand-name prices for an additional six months beyond the initial patent or exclusivity expiration date [1].
---
Sources:
[1] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/pediatric-exclusivity
[2] https://www.fda.gov/patients/pediatric-drug-development/pediatric-research-equity-act-prea
[3] https://drugpatentwatch.com/